The non-intravenous, chemotherapy-sparing combination of dalpiciclib, pyrotinib, and endocrine therapy demonstrated anti-tumor activity and manageable toxicity in the frontline treatment of ER-positive, HER2-positive ABC, supporting its further evaluation as a potential alternative. Here, ESR1 is linked to neoplasm.